Democrats to force vote against short-term health plans

Amy Baxter | | Health Exec | Policy & Regulations

In response to the Trump administration’s decision to expand short-term health plans, Senate Democrats will try to force a vote to block the rule, the Associated Press reported.

The short-term plans provide healthcare coverage up to 12 months under the new rule, with renewal options up to 36 months. Industry stakeholders and consumer groups expressed concerns over the plans, which are not comprehensive, exclude pre-existing conditions and are not subject to other Affordable Care Act (ACA) requirements.

A vote to block the plans, which were previously limited to just three months, could narrowly pass in the Senate, but has a far less chance to be approved in the Republican-dominated House, the AP reported.

Democrats will use the Congressional Review Act, which allows any senator to force a vote on overturning actions by federal agencies under some circumstances.

Dems will try forcing Senate vote against Trump health plan

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

‘A huge win’: CMS significantly increases Medicare payments for cardiac CT
Kentucky AG launches criminal probe after conscious man nearly has organs harvested
FDA announces Class I recall of ventilators after 3 patient injuries
FDA clears AI tool that flags signs of heart disease in chest CT scans
Stewardship Health sale to private equity finalized for $245M
Baxter producing IV solutions ahead of schedule at Asheville-area site

Around the web

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup